Respiratory Drugs in Pharmacology
Learning Objectives
By the end of this page, you should be able to:
- Classify bronchodilators (beta-2 agonists, anticholinergics, methylxanthines) by mechanism and duration of action.
- Explain how inhaled corticosteroids control airway inflammation and why they are not "rescue" drugs.
- Differentiate antihistamine generations and match them to appropriate clinical scenarios.
- Describe how antitussives, expectorants, and mucolytics differ in their action on cough and secretions.
- Apply the stepwise pharmacologic approach used in asthma and COPD management.
- Identify common prescribing errors and drug-specific adverse effects tested in exams.
Quick Answer
Respiratory drugs treat airway narrowing, inflammation, allergy, and excess or thick secretions. Bronchodilators (beta-2 agonists, anticholinergics, methylxanthines) relax airway smooth muscle for quick symptom relief. Inhaled corticosteroids suppress the chronic inflammation that drives asthma, functioning as controller, not rescue, therapy. Antihistamines block H1 receptors to relieve allergic rhinitis and urticaria. Antitussives suppress the cough reflex centrally, while expectorants and mucolytics work on mucus volume and viscosity instead. These drug classes matter because respiratory disease — asthma, COPD, allergic rhinitis, common cold — is one of the most frequent reasons patients seek care, and correctly separating "reliever" from "controller" drugs is a recurring exam and clinical safety point.
Overview
The respiratory tract is a continuous tube — nose, pharynx, larynx, trachea, bronchi, bronchioles, alveoli — lined by smooth muscle, mucus-secreting cells, and cilia. Two things commonly go wrong: the airway lumen narrows (bronchospasm, inflammation, mucus plugging) or the tract becomes irritated and triggers a cough. Respiratory pharmacology is organized around fixing these two problems.
Broadly, drugs fall into four functional groups covered here:
- Bronchodilators — relax smooth muscle to widen the airway (fast, symptomatic).
- Corticosteroids (and other anti-inflammatories like leukotriene modifiers) — reduce the underlying inflammation (slow, disease-modifying).
- Antihistamines — block histamine-mediated allergic symptoms (sneezing, itching, rhinorrhea).
- Antitussives, expectorants, and mucolytics — manage cough and secretions.
Understanding why a drug is dosed the way it is — reliever versus controller, oral versus inhaled — is more valuable for exams than memorizing brand names.
Core Concepts
1. Bronchodilators
Definition: Drugs that relax bronchial smooth muscle, dilating the airway and improving airflow.
Explanation: Airway smooth muscle tone is controlled by a balance of sympathetic (relaxing, via beta-2 receptors) and parasympathetic (contracting, via muscarinic M3 receptors) input, plus intracellular cyclic AMP. Bronchodilators intervene at one of these points.
| Class | Mechanism | Onset/Duration | Examples |
|---|---|---|---|
| Short-acting beta-2 agonists (SABA) | Stimulate beta-2 receptors → increase cAMP → smooth muscle relaxation | Onset minutes, lasts 4–6 h | Salbutamol (albuterol), terbutaline |
| Long-acting beta-2 agonists (LABA) | Same mechanism, lipophilic tail prolongs receptor contact | Onset 15–30 min (formoterol faster), lasts 12 h | Salmeterol, formoterol |
| Short-acting antimuscarinics (SAMA) | Block M3 receptors, preventing acetylcholine-driven bronchoconstriction | Onset 15–30 min, lasts 4–6 h | Ipratropium bromide |
| Long-acting antimuscarinics (LAMA) | Same mechanism, slow receptor dissociation | Lasts 24 h | Tiotropium |
| Methylxanthines | Inhibit phosphodiesterase (raising cAMP) and antagonize adenosine receptors | Oral, narrow therapeutic index | Theophylline |
Example: A patient with sudden wheeze during exercise inhales salbutamol; within minutes, beta-2 receptor activation on bronchial smooth muscle relaxes the airway and the wheeze subsides.
Real-World Example: In an acute asthma attack in the emergency department, nebulized salbutamol is combined with nebulized ipratropium — the two act on different receptors (beta-2 versus muscarinic), giving an additive bronchodilator effect faster than either alone.
Why It Matters: Bronchodilators are the fastest tool for relieving acute airway obstruction, which is why SABAs are the universal "rescue inhaler" across asthma and COPD guidelines.
Common Misunderstanding: Students often assume more frequent SABA use is harmless. In reality, needing a SABA more than twice a week signals poorly controlled asthma and should prompt escalation of controller therapy (inhaled corticosteroids), not just more reliever puffs. Overuse of LABA without a concurrent inhaled corticosteroid has also been linked to increased asthma mortality — LABAs are never prescribed as monotherapy in asthma.
2. Corticosteroids (and Anti-Inflammatory Agents)
Definition: Drugs that suppress airway inflammation by altering gene transcription in airway cells, reducing swelling, mucus hypersecretion, and bronchial hyperreactivity.
Explanation: Inhaled corticosteroids (ICS) diffuse into airway epithelial and immune cells, bind cytoplasmic glucocorticoid receptors, and translocate to the nucleus where they switch off pro-inflammatory genes (cytokines, chemokines) and switch on anti-inflammatory ones. Because this changes gene expression, the effect builds over days to weeks — ICS will not stop an acute attack in progress.
| Class | Mechanism | Example |
|---|---|---|
| Inhaled corticosteroids (ICS) | Suppress transcription of inflammatory mediators | Budesonide, fluticasone, beclomethasone |
| Leukotriene receptor antagonists | Block cysteinyl leukotriene (CysLT1) receptors, preventing bronchoconstriction and mucus secretion | Montelukast |
| Leukotriene synthesis inhibitor | Inhibits 5-lipoxygenase, blocking leukotriene production | Zileuton |
| Phosphodiesterase-4 inhibitors | Raise intracellular cAMP in inflammatory cells, reducing cytokine release (used in severe COPD) | Roflumilast |
Example: A child with mild persistent asthma uses a low-dose ICS inhaler twice daily; over two to three weeks, airway inflammation and hyperreactivity decrease, cutting the frequency of wheezing episodes.
Real-World Example: Montelukast is often added for asthma with a strong allergic/aspirin-sensitive component, or for exercise-induced bronchoconstriction, because leukotrienes are heavily involved in those triggers.
Why It Matters: ICS therapy is the single most important step-up in asthma management — it is the only class shown to reduce exacerbation frequency and mortality by treating the underlying disease rather than the symptom.
Common Misunderstanding: Patients (and sometimes students) confuse ICS with a "rescue" drug because it comes in an inhaler like salbutamol. ICS is a controller — taken daily regardless of symptoms — and stopping it once symptoms improve is a classic cause of relapse. Local side effects (oral candidiasis, dysphonia) are prevented by rinsing the mouth after use, not by skipping doses.
3. Antihistamines
Definition: Drugs that competitively block histamine H1 receptors, reducing allergic symptoms such as sneezing, itching, rhinorrhea, and urticaria.
Explanation: Allergen exposure triggers mast cell degranulation and histamine release, which acts on H1 receptors on nerve endings, blood vessels, and mucus glands to cause itching, vasodilation, and secretion. H1 antihistamines occupy the receptor without activating it, blunting these effects.
| Generation | Features | Examples |
|---|---|---|
| First-generation | Lipophilic, cross blood-brain barrier → sedation, anticholinergic effects | Diphenhydramine, chlorpheniramine |
| Second-generation | Poorly cross blood-brain barrier → minimal sedation, longer duration | Cetirizine, loratadine, fexofenadine |
Example: A patient with seasonal allergic rhinitis takes loratadine each morning; H1 receptor blockade reduces sneezing and nasal itching without daytime drowsiness.
Real-World Example: First-generation antihistamines like diphenhydramine are still used at night for allergic symptoms because their sedating effect is acceptable (or even desired) before sleep, but they are avoided in drivers, the elderly, and anyone needing daytime alertness.
Why It Matters: Antihistamines are first-line for allergic rhinitis, urticaria, and adjunctive treatment in anaphylaxis, making them among the most commonly used respiratory-adjacent drugs.
Common Misunderstanding: Many assume antihistamines relieve nasal congestion. H1 blockade treats itching, sneezing, and rhinorrhea — it does little for the vascular congestion causing a blocked nose, which is why decongestants (e.g., pseudoephedrine) are combined separately for that symptom.
4. Antitussives, Expectorants, and Mucolytics
Definition: Antitussives suppress the cough reflex; expectorants increase and thin respiratory secretions to make coughing more productive; mucolytics chemically break down existing thick mucus.
Explanation: Cough is a reflex arc — irritant receptors in the airway send signals via the vagus nerve to the medullary cough center. Antitussives blunt this reflex either centrally (opioids like codeine, acting on mu-opioid receptors in the cough center) or peripherally (dextromethorphan, benzonatate). Expectorants (guaifenesin) increase the volume and reduce the viscosity of airway secretions so cilia can clear them more easily. Mucolytics (N-acetylcysteine) break disulfide bonds within mucoprotein, directly liquefying thick, tenacious sputum.
| Class | Mechanism | Example |
|---|---|---|
| Antitussive (central) | Suppresses medullary cough center | Codeine, dextromethorphan |
| Antitussive (peripheral) | Anesthetizes stretch receptors in airway | Benzonatate |
| Expectorant | Increases secretion volume, reduces viscosity | Guaifenesin |
| Mucolytic | Breaks disulfide bonds in mucus glycoproteins | N-acetylcysteine |
Example: A patient with a dry, exhausting, non-productive cough from a viral upper respiratory infection is given dextromethorphan to suppress the irritant cough reflex and allow sleep.
Real-World Example: In cystic fibrosis, nebulized N-acetylcysteine or dornase alfa is used specifically because sputum there is unusually thick and mucolytics — not expectorants or suppressants — are needed to clear it.
Why It Matters: Choosing the wrong tool worsens outcomes: suppressing a productive cough with an antitussive can cause mucus retention and infection, while giving an expectorant for a dry, hacking cough does nothing useful.
Common Misunderstanding: Students often lump all "cough medicines" together. A productive cough (bringing up sputum) generally should not be suppressed — it is protective; a dry, non-productive, disruptive cough is the appropriate target for an antitussive.
Visual Learning: Stepwise Drug Therapy in Asthma/COPD
This mirrors real guideline logic (GINA for asthma, GOLD for COPD): rescue bronodilators sit at every step, but the controller backbone escalates from ICS alone toward combination and, ultimately, systemic or biologic therapy. Notice ICS enters early in asthma (inflammation-driven disease) while COPD favors bronchodilators first, with ICS reserved for frequent exacerbators — a frequently tested distinction.
Real-World Applications
- Emergency medicine: Nebulized salbutamol + ipratropium is standard first-line therapy for acute severe asthma and acute COPD exacerbations in the ER.
- Primary care: Correctly stepping a patient up (add ICS) or down (reduce SABA reliance) on the asthma ladder is one of the most common outpatient prescribing decisions.
- Allergy clinics: Second-generation antihistamines are the default for chronic allergic rhinitis and urticaria because they avoid the sedation that limits older agents.
- Palliative and post-surgical care: Codeine-based antitussives are used to suppress distressing, non-productive cough, e.g., after thoracic surgery or in advanced lung cancer.
- Cystic fibrosis and bronchiectasis clinics: Mucolytics and airway clearance techniques are central to preventing infection from mucus stasis.
Key Terms
| Term | Definition |
|---|---|
| Bronchodilator | Drug that relaxes airway smooth muscle to widen the lumen and improve airflow |
| Reliever (rescue) therapy | Fast-acting drug (typically SABA) used to relieve acute symptoms, not to control underlying disease |
| Controller therapy | Daily maintenance drug (typically ICS) that treats the underlying chronic inflammation |
| Beta-2 agonist | Drug stimulating beta-2 adrenergic receptors on airway smooth muscle, raising cAMP and causing relaxation |
| Anticholinergic/antimuscarinic | Drug blocking M3 muscarinic receptors, preventing acetylcholine-induced bronchoconstriction |
| Methylxanthine | Drug class (e.g., theophylline) inhibiting phosphodiesterase, raising cAMP; narrow therapeutic index |
| Inhaled corticosteroid (ICS) | Anti-inflammatory drug suppressing transcription of inflammatory mediators in airway cells |
| Leukotriene | Inflammatory lipid mediator causing bronchoconstriction and mucus secretion; targeted by montelukast |
| H1 antihistamine | Drug blocking histamine H1 receptors, reducing itching, sneezing, and rhinorrhea |
| Antitussive | Drug suppressing the cough reflex, centrally or peripherally |
| Expectorant | Drug increasing and thinning respiratory secretions to aid clearance |
| Mucolytic | Drug chemically breaking down mucus (e.g., disulfide bonds) to reduce viscosity |
Common Mistakes
Misconception 1: "Using a SABA (salbutamol) inhaler more often is fine as long as symptoms improve." Why it's wrong: Frequent SABA use masks worsening airway inflammation without treating it, and is associated with increased risk of severe exacerbations and death. Correct understanding: Needing a SABA more than twice a week is a signal to step up controller (ICS) therapy, not to simply refill the reliever inhaler.
Misconception 2: "Inhaled corticosteroids work immediately, like a bronchodilator." Why it's wrong: ICS act by altering gene transcription, a process that takes days to weeks to produce a clinical effect; they do nothing for an acute bronchospasm happening right now. Correct understanding: ICS are controller therapy taken daily for long-term inflammation control; acute symptoms still require a bronchodilator.
Misconception 3: "All cough medicines are interchangeable — any cough syrup will help any cough." Why it's wrong: Antitussives suppress a reflex that may be protective in a productive cough, while expectorants and mucolytics don't help a dry, irritant cough at all. Correct understanding: Match the drug to the cough type — antitussives for dry/non-productive cough, expectorants or mucolytics when thick secretions need to be cleared.
Comparison and Connections
| Feature | Beta-2 Agonists | Anticholinergics | Inhaled Corticosteroids | Leukotriene Modifiers |
|---|---|---|---|---|
| Onset | Fast (minutes) | Fast–moderate | Slow (days–weeks) | Slow (days) |
| Role | Reliever/controller (LABA) | Reliever/controller (LAMA) | Controller | Add-on controller |
| Mechanism | ↑ cAMP via beta-2 receptor | Block M3 muscarinic receptor | Suppress inflammatory gene transcription | Block/inhibit leukotriene pathway |
| Key risk | Tremor, tachycardia; LABA monotherapy in asthma raises mortality | Dry mouth, urinary retention | Oral candidiasis, dysphonia (local); adrenal suppression (high dose, systemic) | Neuropsychiatric effects (montelukast) |
| Typical use | Asthma, COPD (all severities) | COPD favored; adjunct in severe asthma | Persistent asthma; frequent COPD exacerbators | Allergic/exercise-induced asthma, aspirin-sensitive asthma |
| Feature | Antitussive | Expectorant | Mucolytic |
|---|---|---|---|
| Target | Cough reflex | Secretion volume/consistency | Existing mucus structure |
| Best for | Dry, non-productive cough | Thick secretions needing easier clearance | Very thick, tenacious sputum (e.g., cystic fibrosis) |
| Caution | Avoid in productive cough with infection risk | Limited high-quality efficacy evidence | Can cause bronchospasm in sensitive patients (nebulized NAC) |
Practice Questions
Recall
- Name the three main classes of bronchodilators and give one example of each. Answer guidance: Beta-2 agonists (salbutamol), anticholinergics (ipratropium), methylxanthines (theophylline).
- What is the mechanism of action of inhaled corticosteroids? Answer guidance: They suppress transcription of pro-inflammatory genes in airway cells, reducing inflammation, mucus hypersecretion, and hyperreactivity.
Understanding 3. Why are LABAs never prescribed alone in asthma? Answer guidance: LABA monotherapy has been linked to increased risk of severe exacerbations and asthma-related death; they must be paired with an ICS so the underlying inflammation is also treated. 4. Explain why an antihistamine relieves sneezing and itching but not nasal congestion. Answer guidance: H1 receptors mediate itching/sneezing/secretion via nerve and gland stimulation, but nasal congestion is primarily vascular engorgement, which antihistamines do not directly address — decongestants are needed for that.
Application 5. A COPD patient has frequent exacerbations despite LAMA + LABA therapy. What class would guidelines add next, and why? Answer guidance: Add an inhaled corticosteroid, particularly if the patient has blood eosinophilia, since ICS reduces exacerbation frequency in that subgroup. 6. A child has a dry, exhausting nighttime cough disrupting sleep, with no chest congestion. Which drug class is appropriate and which is not? Answer guidance: An antitussive (e.g., dextromethorphan) is appropriate; an expectorant would not help because there is no thick mucus to clear.
Analysis 7. Compare why ICS is introduced earlier in the asthma stepwise ladder than in the COPD ladder. Answer guidance: Asthma is primarily an inflammatory, eosinophilic disease responsive to corticosteroids from early stages; COPD is driven more by fixed airflow limitation and neutrophilic inflammation, so bronchodilators come first and ICS is reserved for frequent exacerbators. 8. A patient on high-dose theophylline develops nausea, tremor, and arrhythmia. Explain the pharmacological basis and why this drug requires monitoring that beta-2 agonists do not. Answer guidance: Theophylline has a narrow therapeutic index; its therapeutic and toxic plasma concentrations are close together, so small increases (e.g., from drug interactions or reduced clearance) cause phosphodiesterase inhibition and adenosine antagonism severe enough to produce toxicity, requiring blood level monitoring — unlike inhaled beta-2 agonists, which have a wide safety margin at standard doses.
FAQ
1. Why is a rescue inhaler not enough to control asthma long-term? Because a SABA only relaxes airway muscle temporarily — it does not treat the chronic inflammation causing hyperreactivity, so symptoms and exacerbation risk continue unless a controller (ICS) is added.
2. Can inhaled corticosteroids stunt growth in children? Long-term high-dose ICS use has been associated with a small, usually transient reduction in growth velocity; benefits of asthma control generally outweigh this risk, and the lowest effective dose is used with height monitored.
3. Why do first-generation antihistamines cause drowsiness but second-generation ones don't? First-generation agents are lipophilic and cross the blood-brain barrier to block central H1 receptors involved in wakefulness; second-generation antihistamines are designed to be more polar and largely excluded from the brain.
4. Is it safe to combine an expectorant and an antitussive in the same cough syrup? It is common in over-the-counter combination products, but pharmacologically it is somewhat contradictory — the expectorant increases secretions while the antitussive suppresses the reflex meant to clear them, so such combinations are generally discouraged for a genuinely productive cough.
5. Why does theophylline need blood level monitoring but salbutamol doesn't? Theophylline has a narrow therapeutic index and is metabolized by cytochrome P450 enzymes affected by many drug interactions, so small changes in clearance can cause toxicity; salbutamol acts locally via inhalation with a much wider safety margin.
Quick Revision
- Bronchodilators relax smooth muscle: beta-2 agonists (↑cAMP), anticholinergics (block M3), methylxanthines (inhibit phosphodiesterase).
- SABA = reliever (fast, symptomatic); LABA must always be paired with ICS in asthma.
- ICS = controller, works over days–weeks by altering gene transcription; not for acute attacks.
- Needing SABA >2x/week = signal to step up controller therapy.
- Leukotriene modifiers (montelukast) are useful for allergic and exercise-induced asthma.
- Theophylline has a narrow therapeutic index — requires monitoring.
- Antihistamines: first-generation sedating (cross BBB); second-generation non-sedating.
- Antihistamines relieve itching/sneezing/rhinorrhea, not nasal congestion.
- Antitussives suppress cough reflex — use only for dry, non-productive cough.
- Expectorants (guaifenesin) thin/increase secretions; mucolytics (NAC) break disulfide bonds in thick mucus.
- Asthma stepwise therapy escalates ICS-based; COPD escalates bronchodilator-based (LAMA/LABA) with ICS added for frequent exacerbators.
- Combined nebulized SABA + ipratropium is standard acute ER management for severe bronchospasm.
Related Topics
Prerequisites
- Basic respiratory anatomy (trachea, bronchi, bronchioles, alveoli)
- Autonomic nervous system pharmacology (adrenergic and cholinergic receptors)
- General principles of inflammation
Related Topics
- Autonomic Pharmacology (adrenergic/cholinergic agonists and antagonists)
- Anti-inflammatory and Corticosteroid Pharmacology
- Antimicrobial Therapy for Respiratory Infections
Next Topics
- Asthma and COPD clinical management guidelines (GINA/GOLD)
- Pediatric Respiratory Pharmacology
- Pharmacology of Anaphylaxis and Emergency Airway Drugs